Friday, May 16, 2025
5:30 PM – 6:00 PM CT: Registration/Dinner
6:00 PM – 7:30 PM CT: Symposium
Gaylord Opryland Resort
2800 Opryland Drive
Nashville, TN 37214
Meeting Room: Jackson EF
PROGRAM FEATURES
- Downloadable Mixed Reality animations
- ENCOMPASS and CATALYST portal tools and resources
- Create your own personalized poster
PRESENTING FACULTY
 |
David M. Miller, MD PhD FAAD Director, Center for Merkel Cell Carcinoma Co-Director, NMSC Multi-Disciplinary Clinic Massachusetts General Cancer Center Assistant Professor of Medicine and Dermatology Harvard Medical School Boston, Massachusetts |
 |
Vishal Patel, MD Director of Cutaneous Oncology, GW Cancer Center Director of Dermatologic Surgery, GW Department of Dermatology Associate Professor of Dermatology & of Medicine/Oncology George Washington University School of Medicine & Health Sciences Washington, DC |
TARGET AUDIENCE
This activity is designed to meet the educational needs of surgical dermatologists, Mohs surgeons, dermatologists, and other healthcare practitioners who care for patients with advanced/mBCC or CSCC.
LEARNING OBJECTIVES
After completing the activity, learners should be better able to:
- Explain the risk-assessment of patients with non-melanoma skin cancers who may derive optimal benefit with new systemic therapies when compared to Mohs surgery
- Incorporate patient trials data for systemic immunotherapy into the treatment of both advanced cutaneous squamous cell carcinoma and basal cell carcinoma
- Collaborate with other members of the NMSC health care team to provide a multidisciplinary approach to the development of treatment plans for individuals with high risk NMSCs
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
